Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Speculation Mounts In Korea, Biosimilar Play Celltrion Still Seems Likely To Sell To Big Pharma

This article was originally published in PharmAsia News

Executive Summary

Although Celltrion has raised eyebrows by saying it would consider the best interests of Korea’s pharmaceutical industry in a potential sale, most analysts still believe a multinational will win out. Speculation has heated up after a local report singled out AstraZeneca as a potential suitor.

You may also be interested in...



Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma

Samsung Will Develop Biosimilars For U.S. And EU, But Avoids Emerging Markets For Now

SEOUL - Samsung Biologics, which hopes to establish itself as a global contract manufacturer in a long journey to become a global biopharmaceutical company, said it will eventually try to sell its biosimilars in the U.S. and EU markets rather than emerging markets

Korea's Samsung Electronics On Manhunt For Biosimilar Talent As Local Companies Keep Wary Eye On Competition

SEOUL - South Korea's leading biosimilar companies such as LG Life Sciences, Celltrion and others are increasingly wary of Samsung Electronics' ongoing talent search for research and development experts as the company prepares to make its debut in the blooming biosimilar business

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC085201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel